Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in East Asian patients with advanced NSCLC
NCT01500824Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- May 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Objective Response Rate at 33 months. Planned start May 2014; status: withdrawn.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01500824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01500824.